Status:
RECRUITING
An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery
Lead Sponsor:
Bayer
Conditions:
Unresectable Hepatocellular Carcinoma
Eligibility:
All Genders
18+ years
Brief Summary
This is an observational study in which only data will be collected from adults with unresectable hepatocellular carcinoma. These adults should be prescribed a different treatment after treatment with...
Eligibility Criteria
Inclusion
- Adult patients, ≥ 18 years of age on the day of signing informed consent.
- Confirmed diagnosis of uHCC, treated in a first-line setting with AB or another approved 1L-IO combo therapy.
- Decision to initiate treatment with a second-line systemic treatment was made as per investigator's routine treatment practice prior to study enrollment.
- Signed informed consent or (for patients under legal age) signed informed assent by the patient (where applicable) and signed informed consent by parents / legal guardian.
- No participation in an investigational program with interventions outside of routine clinical practice.
Exclusion
- \- Not applicable
Key Trial Info
Start Date :
November 27 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 1 2027
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT06117891
Start Date
November 27 2023
End Date
February 1 2027
Last Update
November 12 2025
Active Locations (20)
Enter a location and click search to find clinical trials sorted by distance.
1
Mercy Medical Center - Medline Healthcare Services LLC
Baltimore, Maryland, United States, 21202
2
University of Michigan Health System
Ann Arbor, Michigan, United States, 48109
3
Roswell Park Comprehensive Cancer Center
Buffalo, New York, United States, 14203
4
University Of Cincinnati Division Of Hematology Oncology - UC Health System
Cincinnati, Ohio, United States, 45219